Azra AI Acquires Thynk Health to Close the Gap Between Imaging and Cancer Care

Azra AI, the leading end-to-end enterprise platform for incidental findings and oncology workflow automation, announced the acquisition of Thynk Health, the specialized leader of lung cancer screening and incidental findings management. The deal unites two of healthcare's most trusted names in imaging-driven care coordination, with a shared goal: ensuring that no patient falls through the cracks between detection, diagnosis, and treatment.

The combined Azra AI and Thynk Health platforms are already deployed across hundreds of hospitals and represent the largest install base in its market segment, including five of the top ten healthcare systems in the United States.  Currently processing well over half a billion clinical reports and messages annually in real time — at the scale and reliability that health systems can trust — the combination of these two platforms further strengthens their leadership position, which translates directly into fewer missed findings, faster follow-up, and stronger patient retention across the enterprise. 

"Health systems are moving beyond fragmented tools and toward true enterprise-wide intelligence platforms," said John Marshall, CEO of Azra AI. "EHRs were not built for this level of complexity, especially when it comes to delivering the specialized clinical workflows that turn a finding into a follow-up and a follow-up into a life saved.  At the same time, disconnected point solutions further exacerbate the problem by creating fragmentation, limiting scale, and widening the gaps in patient care. The future of care is not just managing patients once disease is suspected — it's identifying patients earlier, often before symptoms appear. Azra was built from day one to be something fundamentally different — by leveraging discrete clinical data across the enterprise, we can surface high-risk, asymptomatic patients and accelerate diagnosis of life-threatening conditions. That requires an AI platform built for continuous, longitudinal patient journeys and complex workflows that ensures no patient will fall through the cracks.  This combination with Thynk Health, and their amazing people and technology, accelerates our mission of saving lives every day. The platform we have built is extraordinary, and the excitement inside our two organizations is incredible."

"Too many important imaging findings never lead to action — a missed follow-up, a gap in communication, and a patient's early-stage diagnosis becomes a late-stage one," said Daniel Weeks, CEO of Thynk Health. "That's the problem Thynk was built to solve. Joining Azra gives us the platform depth and reach to deliver continuous, coordinated care with highly actionable data at vast scale across entire health system populations, not just individual programs.  Azra provides an immediate enterprise-wide clinical strategy for health systems' most critical service lines with one platform that spans across the entire longitudinal patient journey — from suspicion past survivorship. Add to that Azra's suite of hands-on clinical services — Navigation, Case Finding, MDM/Tumor Board Coordination, and Strategic Program Execution — and health systems have something no point solution or EHR can offer: a partner that runs alongside them, not just a tool they have to operate themselves. There is simply nothing else like it on the market — one platform, one partner, one mission. We could not be happier with the outcome."

John Marshall will continue as CEO of the combined organization. Daniel Weeks, formerly CEO of Thynk Health, will assume the role of Chief Operating Officer at Azra AI. Both companies will continue supporting existing customer deployments throughout the integration process, with no disruption to current contracts or workflows.